| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neuroimaging Research Unit (Drs. Filippi, Rovaris, Rocca, and Sormani) and Clinical Trials Unit (Dr. Comi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan; Unit of Clinical Epidemiology and Trials (Dr. Sormani), National Institute for Cancer Research, Genoa, Italy; and Health Science Center (Dr. Wolinsky), University of Texas–Houston.
Address correspondence and reprint requests to Dr. M. Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, via Olgettina 60, 20132 Milan, Italy; e-mail: filippi.massimo{at}hsr.it
The authors evaluated whether glatiramer acetate (GA) modifies the severity of tissue damage in 1,722 new lesions from 239 patients with MS enrolled in a placebo-controlled trial monitored with monthly cerebral MRI. The percentage of new lesions that evolved into "black holes" was lower in GA-treated than in placebo patients on scans at 7 (18.9 and 26.3%; p = 0.04) and 8 (15.6 and 31.4%; p = 0.002) months after lesion appearance. GA has a favorable effect on tissue disruption in MS lesions once they are formed.
This article has been cited by other articles:
|
|
 |
|
  D Cadavid, J Cheriyan, J Skurnick, J A Lincoln, L J Wolansky, and S D Cook New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate J. Neurol. Neurosurg. Psychiatry, December 1, 2009; 80(12): 1337 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Bar-Or, J Oger, E Gibbs, M Niino, T Aziz, C Renoux, S Alatab, F. Shi, D Campagnolo, F Jalili, et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Multiple Sclerosis, August 1, 2009; 15(8): 959 - 964. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Riva, V.N. Ikonomidou, J.J. Ostuni, P. van Gelderen, S. Auh, J.M. Ohayon, F. Tovar-Moll, N.D. Richert, J.H. Duyn, and F. Bagnato Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis-Induced Damage AJNR Am. J. Neuroradiol., August 1, 2009; 30(7): 1394 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rovira Tissue-Specific MR Imaging in Multiple Sclerosis AJNR Am. J. Neuroradiol., August 1, 2009; 30(7): 1277 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
L. Mehta, S. Schwid, D. Arnold, G. Cutter, S Aradhye, L. Balcer, P. Calabresi, J. Cohen, P. Cole, R Glanzman, et al. Proof of concept studies for tissue-protective agents in multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 542 - 546. [Abstract] [PDF]
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF]
|
|
|
|
 |
|
 R. P. Lisak Neurodegeneration in multiple sclerosis: Defining the problem Neurology, May 29, 2007; 68(22_suppl_3): S5 - S12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Arnold Evidence for neuroprotection and remyelination using imaging techniques Neurology, May 29, 2007; 68(22_suppl_3): S83 - S90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, M. Filippi, and for the 9006 Study Group Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS Neurology, March 20, 2007; 68(12): 939 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Horani, N. Muhanna, O. Pappo, A. Melhem, C. E. Alvarez, S. Doron, W. Wehbi, K. Dimitrios, S. L. Friedman, and R. Safadi Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G628 - G638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Black, S. Liu, B. C. Hains, C. Y. Saab, and S. G. Waxman Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE Brain, December 1, 2006; 129(12): 3196 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Khan, Y. Shen, C. Caon, F e. Bao, W. Ching, M. Reznar, A. Buccheister, J. Hu, Z. Latif, A. Tselis, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 646 - 651. [Abstract] [PDF]
|
|
|
|
|
|
S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 658 - 668. [Abstract] [PDF]
|
|
|
|
 |
|
 R. T. Naismith and A. H. Cross Multiple Sclerosis and Black Holes: Connecting the Pixels Arch Neurol, November 1, 2005; 62(11): 1666 - 1668. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rizvi and M. A. Agius Current approved options for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S8 - S14. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, June 1, 2004; 10(1_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, May 1, 2004; 10(3_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
K P Johnson, B R Brooks, C C Ford, A D Goodman, R P Lisak, L W Myers, A A Pruitt, M A Rizzo, J W Rose, L P Weiner, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial Multiple Sclerosis, December 1, 2003; 9(6): 585 - 591. [Abstract] [PDF]
|
|
|
|
|
|
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos and P. Duda The Janus face of CNS-directed autoimmune response: a therapeutic challenge Brain, November 1, 2002; 125(11): 2379 - 2380. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Galetta, C. Markowitz, and A. G. Lee Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review Arch Intern Med, October 28, 2002; 162(19): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.S. Wolinsky, G. Comi, M. Filippi, D. Ladkani, S. Kadosh, and G. Shifroni Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained Neurology, October 22, 2002; 59(8): 1284 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Yong Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS Neurology, September 24, 2002; 59(6): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O'Connor Key issues in the diagnosis and treatment of multiple sclerosis: An overview Neurology, September 24, 2002; 59(90063): S1 - 33. [Full Text]
|
|
|
|
|
|
N. D. Richert, M. Filippi, M. Rovaris, M.A. Rocca, M.P. Sormani, G. Comi, and J.S. Wolinsky Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology, May 14, 2002; 58(9): 1440 - 1442. [Full Text] [PDF]
|
|
|
|
|
|
S. Dhib-Jalbut Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis Neurology, April 23, 2002; 58(90084): S3 - 9. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
D. L. Arnold and P.M. Matthews MRI in the diagnosis and management of multiple sclerosis Neurology, April 23, 2002; 58(90084): S23 - 31. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
